From 8c2416f9bbd51120edec46974020a7126d3eded5 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:45:54 +0000 Subject: [PATCH] extract: 2026-03-30-eurheartj-select-mediation-analysis-esc-2024 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...loss-with-inflammation-as-primary-mediator.md | 6 ++++++ ...rheartj-select-mediation-analysis-esc-2024.md | 16 +++++++++++++++- 2 files changed, 21 insertions(+), 1 deletion(-) diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md index 93d7dfbd..45989f77 100644 --- a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md +++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md @@ -25,6 +25,12 @@ This has major implications: (1) the drug should benefit patients across the BMI --- +### Additional Evidence (confirm) +*Source: [[2026-03-30-eurheartj-select-mediation-analysis-esc-2024]] | Added: 2026-03-30* + +ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss. + + Relevant Notes: - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] diff --git a/inbox/queue/2026-03-30-eurheartj-select-mediation-analysis-esc-2024.md b/inbox/queue/2026-03-30-eurheartj-select-mediation-analysis-esc-2024.md index 5764bcb8..d515166c 100644 --- a/inbox/queue/2026-03-30-eurheartj-select-mediation-analysis-esc-2024.md +++ b/inbox/queue/2026-03-30-eurheartj-select-mediation-analysis-esc-2024.md @@ -7,9 +7,13 @@ date: 2024-09-01 domain: health secondary_domains: [] format: conference-abstract -status: unprocessed +status: enrichment priority: medium tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, mediation-analysis, ESC-2024, inflammation, hsCRP, weight-independent] +processed_by: vida +processed_date: 2026-03-30 +enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -52,3 +56,13 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, mediation-analysis, ESC PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Complementary to Lancet 2025 prespecified analysis. Provides specific mediator percentages (hsCRP 42.1%, body weight 19.5%) that the Lancet analysis doesn't separately report. EXTRACTION HINT: Extract as SECONDARY EVIDENCE for the mechanism claim. The Lancet 2025 analysis (queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md) is the primary source. Use this for the specific hsCRP/body weight percentage breakdown which the Lancet paper doesn't separately quantify. Wide CIs = flag for confidence calibration. + + +## Key Facts +- SELECT trial mediation analysis presented at ESC Congress 2024 +- hsCRP mediation estimate: 42.1% +- Body weight mediation estimate: 19.5% +- Waist circumference mediation estimate: 64.0% (widest confidence interval) +- HbA1c mediation estimate: 29.0% +- Joint mediation of all measured factors: 31.4% (95% CI: -30.1% to 143.6%) +- All measured mediators showed statistically significant improvements with semaglutide